Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Completed
NCT03285763Phase 4Updated Jan 23, 2025
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Argentina, Brazil, China, Colombia, Costa Rica +19 more
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An InterventionTerminated
NCT05269667Phase 4Updated Jan 22, 2025
Sponsor: Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder · NMOSD
United States, South Korea, Turkey (Türkiye)
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompleted
NCT03467373Phase 1Updated Jan 17, 2025
Sponsor: Hoffmann-La Roche
B-Cell Lymphoma · Non-Hodgkin Lymphoma
United States, Australia, Canada, Denmark, France +4 more
Development of Novel Clinical Endpoints in Intermediate AMDActive Not Recruiting
NCT03349801N/AUpdated Jan 16, 2025
Sponsor: Frank G. Holz
Age Related Macular Degeneration (AMD)
Denmark, France, Germany, Italy, Netherlands +2 more
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)Terminated
NCT03085810Phase 3Updated Jan 15, 2025
Sponsor: Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
United States, Argentina, Australia, Austria, Belgium +24 more
A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male ParticipantsCompleted
NCT06189508Phase 1Updated Jan 15, 2025
Sponsor: Hoffmann-La Roche
Healthy Male Participants
New Zealand
A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular EdemaCompleted
NCT06771271Phase 1Updated Jan 13, 2025
Sponsor: Hoffmann-La Roche
Diabetic Macular Edema · Uveitic Macular Edema
United States
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerTerminated
NCT03272217Phase 2Updated Jan 7, 2025
Sponsor: Arjun Balar, MD
Urothelial Carcinoma
United States
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's DiseaseCompleted
NCT03664804Phase 1Updated Jan 3, 2025
Sponsor: Hoffmann-La Roche
Huntington's Disease
United States, Canada, Germany, United Kingdom
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompleted
NCT05007613Phase 2Updated Jan 1, 2025
Sponsor: National Taiwan University Hospital
Esophageal Cancer · Metastatic Cancer · Squamous Cell Carcinoma
Taiwan
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaCompleted
NCT00769522Phase 3Updated Dec 31, 2024
Sponsor: German CLL Study Group
Chronic Lymphocytic Leukemia
Germany
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple SclerosisCompleted
NCT00676715Phase 2Updated Dec 31, 2024
Sponsor: Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
United States, Belgium, Bulgaria, Canada, Czechia +13 more
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompleted
NCT02950051Phase 3Updated Dec 30, 2024
Sponsor: German CLL Study Group
Chronic Lymphocytic Leukemia
Austria, Belgium, Denmark, Finland, Germany +5 more
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)Completed
NCT04660539Phase 3Updated Dec 27, 2024
Sponsor: Hoffmann-La Roche
Neuromyelitis Optica Spectrum Disorder
United States, Bulgaria, Canada, Croatia, Germany +13 more
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's DiseaseTerminated
NCT03478956Phase 1Updated Dec 27, 2024
Sponsor: Hoffmann-La Roche
Ulcerative Colitis · Crohn's Disease
Belgium, Poland, Spain, United Kingdom
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)Withdrawn
NCT06331598Phase 2Updated Dec 24, 2024
Sponsor: Hoffmann-La Roche
Solid Tumors
Spain
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruiting
NCT06071871Phase 2Updated Dec 24, 2024
Sponsor: University College, London
Large B-cell Lymphoma
United Kingdom
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsTerminated
NCT04029688Phase 1, Phase 2Updated Dec 20, 2024
Sponsor: Hoffmann-La Roche
Acute Myeloid Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Neuroblastoma · Solid Tumors
United States, Canada, France, Netherlands, Spain +1 more
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)Completed
NCT03946358Phase 2Updated Dec 20, 2024
Sponsor: Centre Hospitalier Universitaire de Besancon
Squamous Cell Carcinoma of the Head and Neck · Anal Canal Cancer · Cervical Cancer
France
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin LymphomaCompleted
NCT03677141Phase 1, Phase 2Updated Dec 18, 2024
Sponsor: Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
United States, Austria, France, Poland, South Korea +1 more
BioFINDER-Brown: Examination of Alzheimer's Disease BiomarkersEnrolling By Invitation
NCT05457998N/AUpdated Dec 17, 2024
Sponsor: Butler Hospital
Alzheimer Disease · Mild Cognitive Impairment · Dementia
United States
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)Recruiting
NCT05017142N/AUpdated Dec 16, 2024
Sponsor: University of Bern
Optic Neuritis · Transverse Myelitis · Acute Disseminated Encephalomyelitis · Multiple Sclerosis
Switzerland
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)Completed
NCT03644186Phase 2Updated Dec 13, 2024
Sponsor: ETOP IBCSG Partners Foundation
Breast Cancer · Estrogen Receptor Positive Tumor · HER2-positive Breast Cancer
Belgium, France, Italy, Switzerland
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer PatientsActive Not Recruiting
NCT03799835Phase 3Updated Dec 11, 2024
Sponsor: UNICANCER
Bladder Cancer
Belgium, France, Spain
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic MetastasesCompleted
NCT04338685Phase 1Updated Dec 9, 2024
Sponsor: Hoffmann-La Roche
Carcinoma, Hepatocellular · Biliary Tract Cancer · Secondary Liver Cancer · Liver Metastases
United States, Denmark, Hong Kong, South Korea, Spain +1 more

Previous page Next page